Enzo Biochem Company Profile (NYSE:ENZ)

About Enzo Biochem (NYSE:ENZ)

Enzo Biochem logoEnzo Biochem, Inc. is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company's segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. It offers a menu of molecular and other clinical laboratory tests or procedures. Enzo Life Sciences manufactures, develops and markets products and tools to clinical research, drug development and bioscience research customers. Enzo Therapeutics is a biopharmaceutical venture that develops multiple approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases. Its products in the development pipeline include a range of assays for detection of various women's health infectious agents, as well as for use in the identification of pathogens for other markets.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: N/A
  • Symbol: NYSE:ENZ
  • CUSIP: N/A
  • Web: www.enzo.com
Capitalization:
  • Market Cap: $418.94 million
  • Outstanding Shares: 46,292,000
Average Prices:
  • 50 Day Moving Avg: $8.74
  • 200 Day Moving Avg: $7.45
  • 52 Week Range: $4.88 - $9.68
P/E:
  • Trailing P/E Ratio: 13.29
  • Foreward P/E Ratio: -82.27
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $105.58 million
  • Price / Sales: 3.97
  • Book Value: $1.89 per share
  • Price / Book: 4.79
Profitability:
  • EBIDTA: ($2,380,000.00)
  • Net Margins: 37.91%
  • Return on Equity: -12.25%
  • Return on Assets: -9.21%
Debt:
  • Current Ratio: 4.35%
  • Quick Ratio: 4.01%
Misc:
  • Average Volume: 250,445 shs.
  • Beta: 1.4
  • Short Ratio: 4.73
 

Frequently Asked Questions for Enzo Biochem (NYSE:ENZ)

What is Enzo Biochem's stock symbol?

Enzo Biochem trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENZ."

How were Enzo Biochem's earnings last quarter?

Enzo Biochem, Inc. (NYSE:ENZ) issued its quarterly earnings results on Monday, March, 13th. The company reported ($0.02) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.04) by $0.02. The company had revenue of $26.26 million for the quarter, compared to the consensus estimate of $26.10 million. Enzo Biochem had a net margin of 37.91% and a negative return on equity of 12.25%. During the same quarter in the prior year, the company earned ($0.07) EPS. View Enzo Biochem's Earnings History.

When will Enzo Biochem make its next earnings announcement?

Enzo Biochem is scheduled to release their next quarterly earnings announcement on Tuesday, June, 6th 2017. View Earnings Estimates for Enzo Biochem.

Who are some of Enzo Biochem's key competitors?

Who owns Enzo Biochem stock?

Enzo Biochem's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (9.06%), Evermore Global Advisors LLC (7.16%), Renaissance Technologies LLC (4.41%), Dimensional Fund Advisors LP (3.96%), Vanguard Group Inc. (3.60%) and Acadian Asset Management LLC (2.57%). View Institutional Ownership Trends for Enzo Biochem.

Who sold Enzo Biochem stock? Who is selling Enzo Biochem stock?

Enzo Biochem's stock was sold by a variety of institutional investors in the last quarter, including Globeflex Capital L P, EAM Investors LLC, Morgan Stanley, ClariVest Asset Management LLC, Spark Investment Management LLC, Wellington Management Group LLP, Dimensional Fund Advisors LP and Citadel Advisors LLC. View Insider Buying and Selling for Enzo Biochem.

Who bought Enzo Biochem stock? Who is buying Enzo Biochem stock?

Enzo Biochem's stock was acquired by a variety of institutional investors in the last quarter, including Berson & Corrado Investment Advisors LLC, Millrace Asset Group Inc., Vanguard Group Inc., Wells Fargo & Company MN, Renaissance Technologies LLC, TIAA CREF Investment Management LLC, MARSHALL WACE ASIA Ltd and Marshall Wace North America L.P.. View Insider Buying and Selling for Enzo Biochem.

How do I buy Enzo Biochem stock?

Shares of Enzo Biochem can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Enzo Biochem stock cost?

One share of Enzo Biochem stock can currently be purchased for approximately $9.05.

Analyst Ratings

Consensus Ratings for Enzo Biochem (NYSE:ENZ) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Enzo Biochem (NYSE:ENZ)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
2/9/2016Dawson JamesReiterated RatingBuyN/AView Rating Details
(Data available from 5/25/2015 forward)

Earnings

Earnings History for Enzo Biochem (NYSE:ENZ)
Earnings by Quarter for Enzo Biochem (NYSE:ENZ)
Earnings History by Quarter for Enzo Biochem (NYSE:ENZ)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
6/6/2017        
3/13/2017Q2 2017($0.04)($0.02)$26.10 million$26.26 millionViewN/AView Earnings Details
12/8/2016Q117($0.05)($0.03)$25.90 million$26.28 millionViewN/AView Earnings Details
10/13/2016Q416($0.06)($0.04)$26.00 million$26.60 millionViewN/AView Earnings Details
6/8/2016Q316($0.06)($0.04)$24.50 million$18.16 millionViewN/AView Earnings Details
3/9/2016Q216($0.06)($0.07)$24.43 million$24.60 millionViewN/AView Earnings Details
12/7/2015Q116($0.05)($0.05)$25.00 million$25.18 millionViewN/AView Earnings Details
10/13/2015Q415($0.06)($0.06)$24.60 million$25.70 millionViewListenView Earnings Details
6/9/2015Q315($0.06)($0.07)$24.40 million$23.99 millionViewN/AView Earnings Details
3/12/2015Q215($0.09)($0.09)$24.20 million$23.09 millionViewN/AView Earnings Details
12/9/2014Q114($0.08)($0.08)$24.50 million$24.82 millionViewListenView Earnings Details
10/9/2014Q4 2014($0.07)($0.06)$23.60 million$24.91 millionViewListenView Earnings Details
6/9/2014Q314($0.09)($0.05)$22.80 million$24.00 millionViewN/AView Earnings Details
3/11/2014Q2($0.08)($0.09)$22.00 million$22.93 millionViewListenView Earnings Details
12/11/2013Q1($0.06)($0.07)ViewListenView Earnings Details
10/16/2013Q413($0.08)$22.00 million$23.30 millionViewListenView Earnings Details
6/10/2013Q3 2013($0.15)$22.20 million$22.60 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Enzo Biochem (NYSE:ENZ)
Current Year EPS Consensus Estimate: $-0.12 EPS
Next Year EPS Consensus Estimate: $-0.11 EPS

Dividends

Dividend History for Enzo Biochem (NYSE:ENZ)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Enzo Biochem (NYSE:ENZ)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Enzo Biochem (NYSE:ENZ)
Latest Headlines for Enzo Biochem (NYSE:ENZ)
Source:
DateHeadline
finance.yahoo.com logoETFs with exposure to Enzo Biochem, Inc. : May 19, 2017
finance.yahoo.com - May 19 at 4:47 PM
americanbankingnews.com logoZacks Investment Research Downgrades Enzo Biochem, Inc. (ENZ) to Hold
www.americanbankingnews.com - May 16 at 6:26 PM
zacks.com logoAfter Gilead Earnings, Buy These Biotech Stocks
www.zacks.com - May 3 at 4:51 PM
americanbankingnews.com logoEnzo Biochem (ENZ) Receives Daily Media Sentiment Score of 0.12
www.americanbankingnews.com - May 2 at 8:22 AM
finance.yahoo.com logoETFs with exposure to Enzo Biochem, Inc. : April 27, 2017
finance.yahoo.com - April 27 at 5:31 PM
americanbankingnews.com logoEnzo Biochem (ENZ) Given News Sentiment Score of 0.56
www.americanbankingnews.com - April 27 at 8:56 AM
americanbankingnews.com logoEnzo Biochem (ENZ) Getting Favorable News Coverage, Analysis Finds
www.americanbankingnews.com - April 20 at 4:24 PM
finance.yahoo.com logoETFs with exposure to Enzo Biochem, Inc. : April 17, 2017
finance.yahoo.com - April 17 at 4:35 PM
americanbankingnews.com logoEnzo Biochem (ENZ) Earning Favorable Media Coverage, Study Shows
www.americanbankingnews.com - April 17 at 3:00 PM
finance.yahoo.com logoEnzo Biochem’s Clinical Laboratory Named an In-Network Provider to the Fourth Largest National Insurer
finance.yahoo.com - April 17 at 11:39 AM
americanbankingnews.com logoEnzo Biochem (ENZ) Receiving Very Positive Media Coverage, Report Shows
www.americanbankingnews.com - April 14 at 8:20 AM
finance.yahoo.com logoETFs with exposure to Enzo Biochem, Inc. : April 5, 2017
finance.yahoo.com - April 7 at 9:38 AM
finance.yahoo.com logoEarnings Estimates Moving Higher for Enzo Biochem (ENZ): Time to Buy?
finance.yahoo.com - March 27 at 11:57 AM
finance.yahoo.com logoEnzo Biochem (ENZ) Shares March Higher, Can It Continue?
finance.yahoo.com - March 24 at 9:13 AM
americanbankingnews.com logoEnzo Biochem, Inc. (ENZ) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - March 22 at 7:16 PM
nasdaq.com logoEnzo Biochem, Inc. (ENZ) Shows Strength: Stock Up 5.2% - Nasdaq
www.nasdaq.com - March 22 at 8:29 AM
zacks.com logoEnzo Biochem, Inc. (ENZ) Shows Strength: Stock Up 5.2%
www.zacks.com - March 21 at 8:27 AM
finance.yahoo.com logoENZO BIOCHEM INC Financials
finance.yahoo.com - March 17 at 5:16 PM
seekingalpha.com logoEnzo Biochem's (ENZ) on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - March 14 at 4:21 PM
us.rd.yahoo.com logoEnzo Biochem Re-Schedules Teleconference to Discuss Second Quarter 2017 Results for This Afternoon, Monday, March 13, 2017 at 4:30 PM E.D.T. Due to Impending Storm
us.rd.yahoo.com - March 13 at 5:03 PM
us.rd.yahoo.com logoEnzo Biochem Reports Increased Second Quarter Operating Results
us.rd.yahoo.com - March 13 at 5:03 PM
biz.yahoo.com logoENZO BIOCHEM INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure
biz.yahoo.com - March 13 at 5:03 PM
biz.yahoo.com logoQ2 2017 Enzo Biochem Inc Earnings Release - After Market Close
biz.yahoo.com - March 13 at 11:56 AM
businesswire.com logoEnzo Biochem Schedules Teleconference to Discuss Second Quarter 2017 Results Tuesday, March 14, 2017 at 8:30 ... - Business Wire (press release)
www.businesswire.com - March 7 at 9:51 PM
finance.yahoo.com logoEnzo Biochem Schedules Teleconference to Discuss Second Quarter 2017 Results Tuesday, March 14, 2017 at 8:30 AM E.T.
finance.yahoo.com - March 6 at 4:46 PM
us.rd.yahoo.com logoGlaxo (GSK) Beats on Q4 Earnings, Posts Dismal '17 View
us.rd.yahoo.com - February 9 at 5:35 PM
finance.yahoo.com logoAmgen's Secondary Hyperparathyroidism Drug Approved in U.S.
finance.yahoo.com - February 8 at 5:30 PM
finance.yahoo.com logoGW Pharma (GWPH) Posts Narrower-than-Expected Loss in Q1
finance.yahoo.com - February 8 at 5:30 PM
finance.yahoo.com logoMallinckrodt (MNK) Tops on Earnings in Transition Quarter
finance.yahoo.com - February 7 at 6:09 PM
us.rd.yahoo.com logoAstraZeneca (AZN) Beats on Q4 Earnings but Misses on Sales
us.rd.yahoo.com - February 3 at 5:23 PM
zacks.com logoSeres Therapeutics (MCRB) Rises: Stock Adds 5% in Session
www.zacks.com - February 1 at 5:33 PM
nasdaq.com logoEndo's (ENDP) Ephedrine Sulfate Injection Gets FDA Approval - Nasdaq
www.nasdaq.com - February 1 at 3:42 AM
zacks.com logoEndo's (ENDP) Ephedrine Sulfate Injection Gets FDA Approval
www.zacks.com - January 31 at 5:41 PM
nasdaq.com logoAstraZeneca's Symbicort Granted Pediatric Exclusivity by FDA - Nasdaq
www.nasdaq.com - January 27 at 6:39 PM
finance.yahoo.com logoPerrigo's (PRGO) Generic Version of Topicort Okayed by FDA
finance.yahoo.com - January 25 at 6:18 PM
finance.yahoo.com logoRoche (RHHBY) Arthritis Drug Actemra sBLA Accepted by FDA
finance.yahoo.com - January 25 at 6:18 PM
us.rd.yahoo.com logoSynergy (SGYP) Trulance Wins FDA Approval for Constipation
us.rd.yahoo.com - January 20 at 6:16 PM

Social

Chart

Enzo Biochem (ENZ) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by MarketBeat.com Staff